Volume 24, Issue 1 pp. 48-55
Research Article

Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer

Haojie Huang

Haojie Huang

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota

Search for more papers by this author
Christopher P. Reed

Christopher P. Reed

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota

Search for more papers by this author
Aderonke Mordi

Aderonke Mordi

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota

Search for more papers by this author
Gwen Lomberk

Gwen Lomberk

Tumor Biology Program, Mayo Clinic/Foundation, Rochester, Minnesota

Search for more papers by this author
Liang Wang

Liang Wang

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota

Search for more papers by this author
Viji Shridhar

Viji Shridhar

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota

Search for more papers by this author
Lynn Hartmann

Lynn Hartmann

Department of Medical Oncology, Mayo Clinic/Foundation, Rochester, Minnesota

Search for more papers by this author
Robert Jenkins

Robert Jenkins

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota

Search for more papers by this author
David I. Smith

Corresponding Author

David I. Smith

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Foundation, 200 First Street S.W., Rochester, MN 55905.Search for more papers by this author

Abstract

We previously showed that FRA7G, an aphidicolin-inducible common fragile site at 7q31.2, colocalized with the common region of loss of heterozygosity (LOH) in a number of different tumors. Based on the sequence analysis of 150 Kb in the FRA7G region, we identified four new polymorphic microsatellite markers. In this article, we have used these four microsatellite markers and eight additional markers from 7q22–32 to analyze the breakage and loss of the region surrounding FRA7G in 49 invasive epithelial ovarian cancers and three borderline ovarian tumors. No allelic loss was detected in the ovarian tumors of borderline malignancy, but 71% (35/49) of the invasive tumors showed LOH at one or more loci in the region analyzed. Of the 12 markers analyzed, most of the markers exhibiting a high frequency of LOH were within FRA7G, and the highest frequency of LOH was seen with the new marker 7G14 (37%, 15/41). Breakpoint analysis in tumors with LOH demonstrated that the frequent loss of DNA sequences seen within the FRA7G region was due to frequent small interstitial deletions and not a result of loss of the whole fragile site region. These findings indicate that FRA7G does play a role in the breakage and loss of 7q sequences in invasive ovarian cancer. In addition, the newly identified markers enable us to further delineate a smallest common region of loss in invasive ovarian tumors to a 150-Kb region flanked by markers D7S486 and 7G14. Genes Chromosomes Cancer 24:48–55, 1999. © 1999 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.